This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
6. References
G. S. Martin, D. M. Mannino, S. Eaton, and M. Moss, The epidemiology of sepsis in the United States from 1979 through 2000, N Engl J Med 348, 1546–1554 (2003).
B. Guidet, P. Aegerter, R. Gauzit, P. Meshaka, and D. Dreyfuss, CUB-Rea Study Group, Incidence and impact of organ dysfunctions associated with sepsis, Chest 127, 942–951 (2005).
B. J. Czermak, V. Sarma, C. L. Pierson, R. L. Warner, M. Huber-Lang, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward, Protective effects of C5a blockade in sepsis, Nat Med 5, 788–792 (1999).
C. Gerard, Complement C5a in sepsis syndrome — too much of a good thing? N Engl J Med 348, 167–169 (2003).
M. Huber-Lang, J. V. Sarma, K. T. Lu, S. R. McGuire, V. A. Padgaonkar, R. F. Guo, E. M. Younkin, R. G. Kunkel, J. Ding, R. Erickson, J. T. Curnutte, and P. A. Ward, Role of C5a in multiorgan failure during sepsis. J Immunol 166, 1193–1199 (2001).
R. F. Guo, N. C. Riedemann, K. D. Bernacki, J. V. Sarma, I. J. Laudes, J. Reuben, E. M. Younkin, T. A. Neff, J. D. Paulauskis, F. S. Zetoune, and P. A. Ward, Neutrophil C5a receptor and the outcome in a rat model of sepsis, FASEB J Exp 17, 1889–1891 (2003).
M. Huber-Lang, E. M. Younkin, V. J. Sarma, S. R. McGuire, K. T. Lu, R. F. Guo, V. A. Padgaonkar, J. T. Curnutte, R. Erickson, and P. A. Ward, Complementinduced impairment of innate immunity during sepsis, J Immunol 169, 3223–3231 (2002).
M. Huber-Lang, N. C. Riedemann, V. J. Sarma, E. M. Younkin, S. R. McGuire, I. J. Laudes, K. T. Lu, R. F. Guo, T. A. Neff, V. A. Padgaonkar, J. Lambris, L. Spruce, D. Mastellos, F. S. Zetoune, and P. A. Ward, Protection of innate immunity by C5aR antagonist in septic mice, FASEB J 16, 1567–1574 (2002).
N. Riedemann, N. Tabriz, T. Barkhausen, M. Van Griensven, D. Kendoff, H. Pape, P. Ward, and C. Kretteck, PI3-Kinase/AKT pathway activation acts as a switch for C5a-induced effects on neutrophil IL-8 generation during inflammation, Shock 23,Suppl. 3, P120 (2005).
J. Cohen, The immunopathogenesis of sepsis, Nature. 420, 885–891 (2002).
R. S. Hotchkiss and I. E. Karl, The pathophysiology and treatment of sepsis. N Engl J Med 348, 138–150 (2003).
P. A. Ward, The dark side of C5a in sepsis, Nat Rev Immunol 4, 133–142 (2004).
R. C. Bone, R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus, R. M. Schein, and W. J. Sibbald, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644–1655 (1992).
S. Stove, T. Welte, T. O. Wagner, A. Kola, A. Klos, W. Bautsch, and J. Kohl, Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 3, 175–183 (1996).
T. Takakuwa, S. Endo, H. Nakae, M. Kikuchi, N. Baba, K. Inada, and M. Yoshida, Blood cytokine and complement levels in patients with sepsis. Res Commun Chem Pathol Pharmacol 84, 291–300 (1994).
H. Nakae, S. Endo, K. Inada, T. Takakuwa, and M. Yoshida, Chronological changes in the complement system in sepsis, Surg Today 26, 225–229 (1996).
K.A. Wichterman, A. E. Baue, and I. H. Chaudry, Sepsis and septic shock-a review of laboratory models and a proposal. J Surg Res 29, 189–201 (1980).
B. J. Czermak, M. Breckwoldt, Z. B. Ravage, M. Huber-Lang, H. Schmal, N. M. Bless, H. P. Friedl, and P. A. Ward, Mechanism of enhanced lung injury during sepsis. Am J Pathol 154, 1057–1065 (1999).
D. H. Hangen, J. H. Stevens, P. S. Satoh, E. W. Hall, P. T. O’Hanley, and T. A. Raffin, Complement levels in septic primates treated with anti-C5a antibodies. J Surg Res 46, 195–199 (1989).
A. Bengtson and M. Heideman, Anaphylatoxin formation of sepsis. Arch Surg 123, 645–649 (1988).
C. Leon, M. J. Rodrigo, A. Tomasa, M. T. Gallart, F. J. Latorre, J. Rius, and J. Brugues, Complement activation in septic shock due to gram-negative and grampositive bacteria. Crit Care Med 10, 308–310 (1982).
N. P. Gerard and C. Gerard, The chemotactic receptor for human C5a anaphylatoxin. Nature 349, 614–617 (1991).
N. Naik, E. Giannini, L. Brouchon, and F. Boulay, Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J Cell Sci 110, 2381–2390 (1997).
M. Furebring, L. D. Hakannsson, P. Venge, B. Nilsson, and J. Sjölin, Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care 6, 363–370 (2002).
I. J. Laudes, J. C. Chur, S. Sikranth, M. Huber-Lang, R. F. Guo, N. Riedemann, J. V. Sarma, A. H. Schmair, and P. A. Ward, Anti-C5a ameliorates coagulation/ fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 160, 1867–1875 (2002).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, LLC
About this paper
Cite this paper
Schreiber, H. et al. (2006). Complement Activation During Sepsis in Humans. In: Lambris, J.D. (eds) Current Topics in Complement. Advances in Experimental Medicine and Biology, vol 586. Springer, Boston, MA. https://doi.org/10.1007/0-387-34134-X_15
Download citation
DOI: https://doi.org/10.1007/0-387-34134-X_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-32231-5
Online ISBN: 978-0-387-34134-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)